In the field of myeloid cancer research, you need meaningful molecular insights fast. Sequential, single-gene approaches for analyzing myeloid disorders can be laborious and time-consuming. As the list of relevant genes increases, a more streamlined approach is needed to expedite the evaluation of myeloid samples. This is particularly true for acute forms of myeloid malignancies that can develop and progress rapidly.
Next-generation sequencing (NGS) with the Oncomine Myeloid Research Assay is an optimal solution, enabling comprehensive assessment of all relevant myeloid mutations and fusion transcripts in a single run. Now, we're taking things to the next level by introducing one-day genomic profiling* for myeloid malignancies on the new Ion Torrent Genexus System.
The Oncomine Myeloid Research Assay is a comprehensive assay that enables simultaneous assessment of both DNA and RNA in a single step. The panel comprises 40 key DNA target genes, 29 driver genes, and a broad fusion panel to cover all of the major myeloid disorders. Gain critical insights into even the most challenging targets, such as FLT3-ITD and CEBPA, with a simple, automated end-to-end workflow for clinical research. Visit the product web page to learn more.
We've recently unveiled a new NGS solution that enables genomic profiling in a single day: the Ion Torrent Genexus System. This technology has the potential to revolutionize myeloid profiling by making it possible to get immediate results for time-sensitive markers such as FLT3-ITD, TP53, CEBPA, NPM1, KIT, PML-RARA, and other key genes in one day*, right in your lab. We're getting closer to that day, and soon the Oncomine Myeloid Research Assay will be available on teh Genexus System.
For Research Use Only. Not for use in diagnostic procedures. *Specimen-to-report workflow will be available after the Ion Torrent Genexus Purification System and integrated reporting capabilities are added in 2020.